

Craig R Underhill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2076631/publications.pdf>

Version: 2024-02-01

82
papers

4,286
citations

159525

30
h-index

110317

64
g-index

84
all docs

84
docs citations

84
times ranked

5673
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring Australian regional cancer patients'™ experiences of clinical trial participation via telehealth. <i>Journal of Telemedicine and Telecare</i> , 2022, 28, 508-516.	1.4	10
2	Psychosocial well-being and supportive care needs of cancer patients and survivors living in rural or regional areas: a systematic review from 2010 to 2021. <i>Supportive Care in Cancer</i> , 2022, 30, 1021-1064.	1.0	29
3	Teletrials, the new norm? Expert recommendations for teletrials into the future: Findings from the Clinical Oncology Society of Australia Clinical Trial Research Professionals Group Workshop. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 650-659.	0.7	4
4	Sequential immunotherapy in rare variant renal cell carcinoma: final report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 4537-4537.	0.8	3
5	Risk assessment model potency to detect patients most likely to benefit from thromboprophylaxis: An application of the TARGET-TP score. <i>Journal of Clinical Oncology</i> , 2022, 40, 12116-12116.	0.8	0
6	Telehealth in cancer care: during and beyond the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2021, 51, 125-133.	0.5	59
7	Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. <i>Cancer Cell</i> , 2021, 39, 592-593.	7.7	41
8	Improving recruitment to clinical trials for regional and rural cancer patients through a regionally based clinical trials network. <i>Medical Journal of Australia</i> , 2021, 214, 453.	0.8	4
9	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	3.9	88
10	Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours. <i>Internal Medicine Journal</i> , 2021, 51, 955-959.	0.5	4
11	Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2020, 61, 91-97.	0.6	6
12	Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020, 50, 1282-1285.	0.5	9
13	Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2020, 6, 1405.	3.4	157
14	Teletrials: implementation of a new paradigm for clinical trials. <i>Medical Journal of Australia</i> , 2020, 213, 263.	0.8	19
15	The Victorian Lung Cancer Service Redesign Project: Impacts of a Quality Improvement collaborative on timeliness and management in lung cancer. <i>Internal Medicine Journal</i> , 2020, , .	0.5	3
16	Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2020, 16, 467-482.	1.4	56
17	Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 4454-4459.	3.2	110
18	A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105. <i>Journal of Clinical Oncology</i> , 2019, 37, e14006-e14006.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	5.1	183
20	Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 887-898.	1.1	10
21	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	1.0	54
22	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, 313-319.	1.0	9
23	Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. <i>British Journal of Haematology</i> , 2017, 177, 441-448.	1.2	21
24	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	5.1	293
25	Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3572-3572.	0.8	1
26	Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results. <i>Clinical Cancer Research</i> , 2016, 22, 4559-4566.	3.2	56
27	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2258-2264.	0.8	52
28	Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services. <i>Internal Medicine Journal</i> , 2016, 46, 964-969.	0.5	8
29	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> , 2016, 16, 339.	1.1	15
30	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	0.6	122
31	Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. <i>British Journal of Cancer</i> , 2016, 114, 505-509.	2.9	43
32	Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 401-408.	1.0	27
33	Oncology service initiatives and research in regional Australia. <i>Australian Journal of Rural Health</i> , 2015, 23, 40-48.	0.7	17
34	Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials. <i>Blood</i> , 2015, 126, 4236-4236.	0.6	2
35	Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors. <i>Blood</i> , 2015, 126, 5375-5375.	0.6	0
36	Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study. <i>Internal Medicine Journal</i> , 2014, 44, 813-817.	0.5	11

#	ARTICLE	IF	CITATIONS
37	Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC).. Journal of Clinical Oncology, 2014, 32, 11015-11015.	0.8	10
38	Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 phase II PAN1 study.. Journal of Clinical Oncology, 2014, 32, 228-228.	0.8	2
39	Prospective evaluation of <i>KRAS, NRAS, BRAF</i>, and <i>PI3KCA</i> mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 70 of Clinical Oncology, 2014, 32, e14536-e14536.	0.8	0
40	Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer, 2013, 21, 1561-1568.	1.0	25
41	Are visiting oncologists enough? A qualitative study of the needs of Australian rural and regional cancer patients, carers and health professionals. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 226-238.	0.7	26
42	Phase I study of tremelimumab (CP-675â€™206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. British Journal of Cancer, 2013, 108, 1998-2004.	2.9	62
43	The GOFURTO Study: AGITG Phase II Study of fixed dose rate gemcitabineâ€™oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer, 2012, 106, 61-69.	2.9	14
44	Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review. Supportive Care in Cancer, 2012, 20, 1-22.	1.0	207
45	Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Internal Medicine Journal, 2011, 41, 75-81.	0.5	27
46	An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Internal Medicine Journal, 2011, 41, 110-120.	0.5	22
47	Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemotherapy and Pharmacology, 2011, 67, 153-163.	1.1	45
48	Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptorâ€™Positive Metastatic Breast Cancer: A Randomized Phase II Study. Clinical Cancer Research, 2011, 17, 1147-1159.	3.2	158
49	A review of PARP inhibitors: from bench to bedside. Annals of Oncology, 2011, 22, 268-279.	0.6	198
50	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood, 2011, 118, 302-302.	0.6	28
51	Reaching Further with Online Education? The Development of an Effective Online Program in Palliative Oncology. Journal of Cancer Education, 2010, 25, 317-323.	0.6	21
52	Mentoring in the management of hematological malignancies. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 28-34.	0.7	4
53	Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Annals of Oncology, 2010, 21, 1302-1307.	0.6	52
54	Mapping oncology services in regional and rural Australia. Australian Journal of Rural Health, 2009, 17, 321-329.	0.7	80

#	ARTICLE	IF	CITATIONS
55	Predictive signatures for chemotherapy sensitivity in breast cancer: Are they ready for use in the clinic?. <i>European Journal of Cancer</i> , 2009, 45, 1733-1743.	1.3	32
56	An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 338-341.	0.6	46
57	Maintaining Imatinib 600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.. <i>Blood</i> , 2009, 114, 1125-1125.	0.6	2
58	The Tolerability of Combination Therapy with Thalidomide and 5-Azacididine in Patients with Advanced Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2009, 114, 1749-1749.	0.6	1
59	A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. <i>Cancer</i> , 2008, 113, 3192-3198.	2.0	11
60	Attitudes of advanced Australian medical oncology trainees to rural practice. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 34-41.	0.7	2
61	Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. <i>Blood</i> , 2008, 112, 3965-3973.	0.6	160
62	Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2007, 97, 464-471.	2.9	35
63	A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer. <i>Oncology</i> , 2007, 73, 9-20.	0.9	18
64	Inequity in rural cancer survival in Australia is not an insurmountable problem. <i>Medical Journal of Australia</i> , 2006, 185, 479-480.	0.8	27
65	Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 460-464.	3.2	129
66	An Educational Workshop Program for Rural Practitioners to Encourage Best Practice for Delivery of Systemic Adjuvant Therapy. <i>Journal of Cancer Education</i> , 2006, 21, 35-39.	0.6	8
67	A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2005, 11, 5504-5514.	3.2	50
68	A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 49, 401-412.	0.9	27
69	Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. <i>Haematologica</i> , 2005, 90, 700-2.	1.7	23
70	A Comparison of Acute and Delayed Infection Rates among Patients with Indolent Lymphoid Malignancies Receiving Fludarabine(F) and Cyclophosphamide(C) with or without Rituximab(R).. <i>Blood</i> , 2004, 104, 3313-3313.	0.6	0
71	A Stratified Risk-Adapted Approach to Lymphoma Salvage in an Outpatient Setting.. <i>Blood</i> , 2004, 104, 4597-4597.	0.6	1
72	Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. <i>Blood</i> , 2003, 102, 69-77.	0.6	129

#	ARTICLE	IF	CITATIONS
73	Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. <i>Medical Journal of Australia</i> , 2003, 178, 412-413.	0.8	2
74	A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2003, 9, 2056-65.	3.2	19
75	Aplastic anemia as a late complication of thymoma in remission. <i>European Journal of Haematology</i> , 2002, 68, 389-391.	1.1	24
76	Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 32, 173-178.	0.9	9
77	Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. <i>Anti-Cancer Drugs</i> , 2001, 12, 647-652.	0.7	15
78	Enhancement of Platelet Recovery After Myelosuppressive Chemotherapy by Recombinant Human Megakaryocyte Growth and Development Factor in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2852-2861.	0.8	59
79	KRN8602 (MX2-Hydrochloride): An Active New Agent for the Treatment of Recurrent High-Grade Glioma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2579-2579.	0.8	16
80	Treatment of Invasive Thymoma With Single-Agent Ifosfamide. <i>Journal of Clinical Oncology</i> , 1999, 17, 2737-2737.	0.8	88
81	Thrombopoietin. <i>BioDrugs</i> , 1999, 11, 261-276.	2.2	6
82	Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.. <i>Journal of Clinical Oncology</i> , 1997, 15, 261-267.	0.8	835